Pliant Therapeutics, Inc.PLRXNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

15 analysts·Moderate coverage

53%

Rating Distribution

Strong Buy

00%

Buy

853%

Hold

640%

Sell

17%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 2474% higher.

Bear Case

$2.00

+65%

Consensus

$31.14

+2474%

Bull Case

$48.00

+3867%

Price Range15 analysts

Low

Consensus

High

$2.00

$48.00

Current Target

Current Price

$1.21

Upside to Target

$29.93

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.80(6 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+500.00%

EPS—

FY2028

Rev+0.00%

EPS—

FY2029

Rev+0.00%

EPS—

Earnings Surprises

Beat rate:50%(6/12 quarters)

Avg surprise:+1.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Mar 3, 2025Stifel Nicolaus

Pliant Therapeutics downgraded to Hold from Buy at Stifel

Target:$3.00

+117.4%from $1.38

Mar 3, 2025Leerink Partners

Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink

Target:$2.00

+44.9%from $1.38

Sep 13, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX)

Target:$38.00

+220.9%from $11.84

Sep 9, 2024Leerink Partners

Pliant Therapeutics assumed with an Outperform at Leerink

Target:$33.00

+156.4%from $12.87

May 23, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX)

Target:$40.00

+188.8%from $13.85

May 7, 2024Stifel Nicolaus

Pliant Therapeutics (PLRX) PT Lowered to $32 at Stifel

Target:$32.00

+130.1%from $13.91

May 7, 2024Oppenheimer

Pliant Therapeutics (PLRX) PT Raised to $48 at Oppenheimer

Target:$48.00

+248.1%from $13.79

May 7, 2024H.C. Wainwright

Pliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright

Target:$36.00

+161.1%from $13.79

May 7, 2024RBC Capital

Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital

Target:$45.00

+226.3%from $13.79

Dec 7, 2022J.P. Morgan

JP Morgan Initiates Coverage On Pliant Therapeutics with Overweight Rating, Announces Price Target of $42

Target:$42.00

+144.5%from $17.18

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance